or Baltimore groups. [7] [8] [9] Thus, in this study, examination was made of changes in hemostatic parameters in children with VOD after BMT. Some parameters appeared appliHepatic veno-occlusive disease (VOD) is a major complication after bone marrow transplantation (BMT). Its cable as markers for VOD and the coagulation-fibrinolysis system was shown to possibly contribute to VOD. prediction, diagnosis and treatment remain unclear. Examination was made of changes in hemostatic parameters in patients with or without VOD after BMT.
+ LPAM 210 mg/m 2 to four patients, antithymoHepatic veno-occlusive disease (VOD) is a major compliglobulin (ATG) 10 mg/kg + CY 200 mg/kg to two patients, cation of bone marrow transplantation (BMT). Its fre-BU 16 mg/kg + CY 200 mg/kg + TEPA 300 mg/m 2 to one quency varies greatly from 1 to 54%, 1,2 and its high morpatient and BU 16 mg/kg + LPAM 210 mg/m 2 to one tality (30-50%) has not improved.
3-6 VOD is characterized patient. by hyperbilirubinemia, painful hepatomegaly and ascites
Ten patients who had undergone BMT from HLAafter BMT, following chemo-radiotherapy conditioning.
matched siblings received cyclosporin A (CsA) alone VOD may possibly arise from injury or disruption of the and/or methotrexate (MTX) as prophylaxis for acute endothelium lining the sinusoids and pores connected to the GVHD, and 10 patients marrow grafts from HLA-matched hepatic venular lumen. Endothelial injury causes activation unrelated donors or HLA-mismatched families received of the coagulation system and post-sinusoidal obstruction, FK506. but the pathogenesis is not clear and the diagnosis of VOD To prevent VOD, heparin (100 U/kg/day) was continuis based only on clinical criteria developed by the Seattle ously infused from days −8 to 30 after BMT. Diagnosis of VOD was based on the Baltimore group criteria: hyperbilirubinemia greater than or equal to 2 mg/dl Correspondence: Dr K Kawa-Ha, Department of Pediatrics, Osaka Medibefore day 21 after transplant and at least two of the follow- gain of greater than 5% from baseline. 8 
Results
Acute GVHD Grade 0-1 5 2 Grade II-IV 8 5 Of the 27 patients, eight developed VOD, ( 12 Gy + thiotepa (TEPA) (600 mg/m 2 ) + melphalan (LPAM) (140 mg/m 2 ). Although patients with VOD Blood sampling received the recombinant tissue plasminogen activator (rt-PA) and prostaglandin E1 (PGE1), five of the eight died of Venous blood was collected in 1/10th vol of 3.8% sodium multiorgan failure (Table 2) . pre-mortum liver biopsies citrate. Plasma samples were separated by centrifugation at were not done. Post-mortum liver biopsies were performed 2000 g for 10 min, 4°C and stored at −80°C until use.
in two patients; one was proven VOD, but the other failed Samples were collected before the conditioning regimen to show typical histological VOD findings. and on days 0, 7, 14, 21 and 28 after BMT.
Endothelial markers Laboratory methods
In the VOD patients, t-PA and PAI-1 significantly increased Endothelial markers: The tissue plasminogen activator (tduring the post-transplant period (Figures 1 and 2 ). Sig-PA), plasminogen activator inhibitor 1 (PAI-1), thrombonificantly high t-PA and PAI-1 were observed on days 21 modulin (TM) and von Willebrand factor (vWF) were meaand 28 after BMT (P Ͻ0.05). vWF activity increased after sured by enzyme immunoassay (EIA) using commercial BMT, but not significantly, and TM showed no significant kits (t-PA:TintElize t-PA and PAI-1 1:TintElize PAI-1 1; change (Table 3) . Bio-pool, Umea, Sweden. TM:TM test; Teijin, Tokyo, Japan. vWF:Asserachromm vWF; Boeringer, Mannheim, Germany).
Coagulation-fibrinolysis markers
Patients with VOD had significantly lower FBG on days Coagulation-fibrinolysis markers: Factor VII activity 21 and 28 after BMT (P Ͻ0.05) (Figure 3 ). Their PLG (F.VII) was determined by a one-stage clotting assay using activity was low on days 0 and 14 after BMT, before VOD deficient plasma (George King BioMedical, Kansas, USA). TAT and PIC were essentially the same in the VOD and (PLG) were assessed using a COBAS MIRA S coagulonon-VOD groups ( Days after BMT t-PA (ng/ml) * P = 0.021 BMT (P Ͻ0.05) ( Figure 5 ). Protein C activity did not change significantly (Table 3) . patients with VOD after BMT have been studied. Although the numbers of patients in all reports have been small and conclusions inconsistent, 10-16 significant decreases in proFibrogenesis marker tein C (PC) and factor VII (F.VII), and increase in Nterminal propeptide for type III procollagen (P-III-P) have VOD and non-VOD patient, procollagen type III (P-III-P) essentially remained unchanged (Table 3) .
been reported. In the present study, some other parameters were found to apparently be good markers for VOD, and the coagulation-fibrinolysis system appeared to be a contributory facDiscussion tor in VOD. Of the 14 hemostatic parameters examined, tissue plasminogen activator (t-PA), plasminogen activator Hepatic VOD may possibly be associated with coagulation, but the pathogenesis is not clear. Few useful markers are inhibitor 1 (PAI-1), fibrinogen (FBG), AT-III and plasminogen (PLG) were observed to have changed in the available for diagnosing VOD, and the diagnosis is based only on clinical criteria. Hemostatic parameters VOD patients. t-PA and PAI-1 increased significantly. At the onset of VOD, a significant decrease in FBG was (coagulation-fibrinolysis factors and endothelial markers) in observed. Prior to that, AT-III and PLG activity was sigby activation and/or damage to endothelial cells following an increase in serum tissue necrosis factor ␣ (TNF␣). nificantly low. Significant changes in protein C (PC), factor VII (F.VII) and P-III-P have been reported, but were not Vanhinsbergh et al 18 found a significant increase in t-PA and PAI-1 following infusion of recombinant human seen in this study.
The occurrence of VOD may be closely related to hyper-TNF␣. These coagulation factors significantly increased with VOD in this study. coagulability. Seeber et al 17 reported endothelial coagulation factors such as t-PA, PAI-1 and vWF to be released
Seven of the present patients who developed VOD were developed severe (grade ϾII) acute graft-versus-host disease (aGVHD). Endothelial cell activation and/or damage by cytokines possibly due to aGVHD, may precede VOD. Following high-dose radio-chemotherapy and severe aGVHD, endothelial cell damage may be more profound, and many cytokines released at the onset of aGVHD may activate endothelial cells. Tissue plasminogen activator (t-PA) accelerates change from plasminogen (PLG) to plasmin, and subsequently plasmin promotes fibrinolysis. PAI-1 inhibits t-PA functioning. In this study, an increase in PAI-1 was a major finding. Though t-PA rose among VOD patients, a significantly high level of t-PA disappeared by day 28 after BMT. PAI-1 released impedes fibrinolysis by inhibiting t-PA, and this leads to hypercoagulability which lant that inhibits the activity of thrombin, factor X (F.X) and factor IX (F.IX) in the coagulation system. Plasminogen (PLG) is activated by plasminogen activators, and then stimulates fibrinolysis. It thus follows that soon after BMT, low AT-III and PLG cause hypercoagulability and may be risk factors of VOD. The high mortality from VOD has not improved. Although various drugs such as heparin, pentoxifylline, prostaglandin E1 (PGE1), ursodepxycholic acid are used to prevent VOD, their efficacy is uncertain. [19] [20] [21] [22] [23] There is no consistently effective therapy for VOD, although a few case reports recommend recombinant tissue plasminogen activator (rt-PA) as treatment. [24] [25] [26] [27] All VOD patients in this study received continuous infusions of heparin, and two received AT-III to keep the and two received prophylactic AT-III. Treatment with rt-PA and the prophylactic use of AT-III for VOD may be effective, because an increase in PAI-1 and low AT-III may accelerate hypercoagulability leading to VOD.
Hypercoagulability following endothelial cell activation and/or damage by cytokines may contribute to the onset of VOD, and increase in t-PA and PAI-1 and decrease in FBG may be useful markers for diagnosing VOD. Low AT-III and PLG may possibly serve as predictive markers for VOD. 
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